Demographics and baseline characteristics
| Pooled placebo (n=12) | Anifrolumab | |||
| 300 mg SC (n=6) | 300 mg IV (n=6) | 600 mg SC (n=6) | ||
| Age (years), median (range) | 38 (22–55) | 26 (20–39) | 29 (21–43) | 27 (19–33) |
| Female, n (%) | 4 (33) | 4 (67) | 1 (17) | 2 (33) |
| Race, n (%) | ||||
| White | 5 (42) | 1 (17) | 2 (33) | 1 (17) |
| Black or African-American | 6 (50) | 5 (83) | 3 (50) | 5 (83) |
| Other * | 1 (8) | 0 (0) | 1 (17) | 0 (0) |
| Body weight (kg), median (range) | 83 (60–103) | 74 (51–96) | 79 (64–91) | 71 (51–86) |
| Height (cm), median (range) | 181 (155–189) | 169 (155–180) | 173 (161–178) | 175 (163–181) |
| BMI (kg/m2), mean (SD) | 26.0 (2.6) | 26.0 (3.8) | 26.6 (2.3) | 22.9 (2.5) |
*Native Hawaiian or other Pacific Islander or Asian.
BMI, body mass index; IV, intravenous; SC, subcutaneous.